Insomnia in Parkinson’s Disease

  • Margaret ParkEmail author
  • Cynthia L. Comella


Insomnia is the most common sleep disorder in Parkinson’s disease (PD). Sleep maintenance insomnia is the most common type of insomnia in this population. The pathophysiology of insomnia is complex and not fully understood. Contributing factors to insomnia in PD include complex medication regimens and comorbidities associated with the disease. A dedicated sleep interview that includes patients’ bed partners or care givers is a necessary diagnostic step in the management of insomnia. Treatment options include non-pharmacological and pharmacological approaches.


Deep Brain Stimulation Sleep Disorder Insomnia Symptom Sleep Diary Sodium Oxybate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in parkinson’s disease. Mov Disord. 1990;5(4):280–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007;8 Suppl 4:S27–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Adler CH, Thorpy MJ. Sleep issues in parkinson’s disease. Neurology. 2005;64(12 Suppl 3):S12–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Stavitsky K, Neargarder S, Bogdanova Y, McNamara P, Cronin-Golomb A. The impact of sleep quality on cognitive functioning in parkinson’s disease. J Int Neuropsychol Soc. 2012;18(1):108–17.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Happe S, Berger K, FAQT Study Investigators. The association between caregiver burden and sleep disturbances in partners of patients with parkinson’s disease. Age Ageing. 2002;31(5):349–54.CrossRefPubMedGoogle Scholar
  6. 6.
    Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM. Nocturnal sleep disturbances and daytime dysfunction in patients with parkinson’s disease and in their caregivers. Parkinsonism Relat Disord. 2004;10(3):157–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of parkinson’s disease. Clin Neuropharmacol. 1988;11(6):512–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in parkinson’s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000;69(5):584–9.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Kryger M, Roth T, Dement W. Principles and practices of sleep medicine. Saint Louis: Elsevier; 2011.Google Scholar
  10. 10.
    American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.Google Scholar
  11. 11.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychaitric Publishing; 2013.CrossRefGoogle Scholar
  12. 12.
    World Health Organization (WHO). International classification of diseases, 10th revision (ICD-10). Geneva: World Health Organization; 1992.Google Scholar
  13. 13.
    Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in parkinson’s disease. J Parkinsons Dis. 2014;4(2):211–21.PubMedGoogle Scholar
  14. 14.
    Perlis ML, Giles DE, Mendelson WB, Bootzin RR, Wyatt JK. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J Sleep Res. 1997;6(3):179–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.CrossRefPubMedGoogle Scholar
  16. 16.
    Tijero B, Somme J, Gomez-Esteban JC, Berganzo K, Adhikari I, Lezcano E, et al. Relationship between sleep and dysautonomic symptoms assessed by self-report scales. Mov Disord. 2011;26(10):1967–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in parkinson’s disease. Am J Geriatr Psychiatry. 1999;7(2):110–8.PubMedGoogle Scholar
  18. 18.
    Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in parkinson’s disease. Mov Disord. 2008;23(2):183–9; quiz 313.CrossRefPubMedGoogle Scholar
  19. 19.
    Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89–98.CrossRefPubMedGoogle Scholar
  20. 20.
    Riemann D, Spiegelhalder K, Feige B, Voderholzer U, Berger M, Perlis M, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Trotti LM, Rye DB. Neurobiology of sleep: the role of dopamine in parkinson’s disease. In: Chaudhuri KR, Tolosa E, Schapira A, Poewe W, editors. Non-motor symptoms in Parkinson’s disease. Oxford: Oxford University Press; 2009. p. 165–76.CrossRefGoogle Scholar
  22. 22.
    Leeman AL, O’Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, et al. Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol. 1987;24(5):637–43.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in parkinson disease: a controlled study using actigraphy. Neurology. 2005;64(8):1450–1.CrossRefPubMedGoogle Scholar
  24. 24.
    Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3–4):497–504.CrossRefPubMedGoogle Scholar
  25. 25.
    Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248(1–2):78–83.CrossRefPubMedGoogle Scholar
  26. 26.
    Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of parkinson’s disease. Brain. 2008;131(Pt 1):e87.PubMedGoogle Scholar
  27. 27.
    Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 2007;78(5):476–9.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Winkelman JW, Buxton OM, Jensen JE, Benson KL, O’Connor SP, Wang W, et al. Reduced brain GABA in primary insomnia: preliminary data from 4 T proton magnetic resonance spectroscopy (1H-MRS). Sleep. 2008;31(11):1499–506.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Buysse DJ. Insomnia. JAMA. 2013;309(7):706–16.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Hogl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, et al. Scales to assess sleep impairment in parkinson’s disease: critique and recommendations. Mov Disord. 2010;25(16):2704–16.CrossRefPubMedGoogle Scholar
  32. 32.
    Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, et al. The parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629–35.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in parkinson disease. Sleep. 2003;26(8):1049–54.PubMedGoogle Scholar
  34. 34.
    Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM. Recommendations for a standard research assessment of insomnia. Sleep. 2006;29(9):1155–73.PubMedGoogle Scholar
  35. 35.
    Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012;35(2):287–302.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Ong JC, Suh S. Diagnostic tools for insomnia. In: Kushida C, editor. The encyclopedia of sleep. Waltham: Academic; 2013. p. 268–73.CrossRefGoogle Scholar
  37. 37.
    Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26(3):342–92.PubMedGoogle Scholar
  38. 38.
    Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007;30(4):519–29.PubMedGoogle Scholar
  39. 39.
    Morgenthaler T, Kramer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update an american academy of sleep medicine report. Sleep. 2006;29(11):1415–9.PubMedGoogle Scholar
  40. 40.
    Ong JC, Crisostomo MI. The more the merrier? Working towards multidisciplinary management of obstructive sleep apnea and comorbid insomnia. J Clin Psychol. 2013;69(10):1066–77.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and parkinson’s disease. Eur J Neurol. 2010;17(4):550–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with alzheimer’s and parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18(3):285–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect. 1993;5(3):227–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Rios RS, Creti L, Fichten CS, Bailes S, Libman E, Pelletier A, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with parkinson’s disease – A randomized study. Parkinsonism Relat Disord. 2013. (
  45. 45.
    Bootzin RR, Epstein D, Wood JM. Stimulus control instructions. In: Hauri PJ, editor. Case studies in insomnia. New York: Plenum Press; 1991. p. 19–28.CrossRefGoogle Scholar
  46. 46.
    Hauri PJ. Current concepts: the sleep disorders. Kalamazoo: The Upjohn Company; 1977.Google Scholar
  47. 47.
    Morin CM, Stone J, Trinkle D, Mercer J, Remsberg S. Dysfunctional beliefs and attitudes about sleep among older adults with and without insomnia complaints. Psychol Aging. 1993;8(3):463–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Ong JC, Cvengros JA, Wyatt JK. Cognitive behavioral treatment for insomnia. Psychatr Ann. 2008;38:590–5.CrossRefGoogle Scholar
  49. 49.
    Stepanski EJ. Hypnotics should not be considered for the initial treatment of chronic insomnia. Con. J Clin Sleep Med. 2005;1(2):125–8.PubMedGoogle Scholar
  50. 50.
    Bruin VM, Bittencourt LR, Tufik S. Sleep-wake disturbances in parkinson’s disease: current evidence regarding diagnostic and therapeutic decisions. Eur Neurol. 2012;67(5):257–67.CrossRefPubMedGoogle Scholar
  51. 51.
    Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in parkinson’s disease. Mov Disord. 1995;10(3):337–40.CrossRefPubMedGoogle Scholar
  52. 52.
    Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6(2):107–13.CrossRefPubMedGoogle Scholar
  53. 53.
    Walsh JK, Roth T. Pharmacologic treatment of insomnia: benzodiazepine receptor agonists. In: Kryger MH, Roth T, Dement WC, editors. Principles and practices of sleep medicine. 5th ed. St Louis: Elsevier; 2011. p. 905–15.CrossRefGoogle Scholar
  54. 54.
    Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, et al. Treatment of insomnia in parkinson’s disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708–14.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Walsh JK, Erman M, Erwin CW, Jamieson A, Mahowald M, Regestein Q, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13(3):191–8.CrossRefGoogle Scholar
  56. 56.
    Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in parkinson disease: results from an open-label trial. Clin Neuropharmacol. 2005;28(4):185–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20(12):1151–8.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7(4):312–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in parkinson’s disease. Sleep Med. 2005;6(5):459–66.CrossRefPubMedGoogle Scholar
  60. 60.
    Ondo WG, Perkins T, Swick T, Hull Jr KL, Jimenez JE, Garris TS, et al. Sodium oxybate for excessive daytime sleepiness in parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65(10):1337–40.CrossRefPubMedGoogle Scholar
  61. 61.
    Arnulf I, Bejjani BP, Garma L, Bonnet AM, Houeto JL, Damier P, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology. 2000;55(11):1732–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  1. 1.Rush University Medical Center, Sleep Disorders Service and Reacher CenterChicagoUSA
  2. 2.Department of Neurological SciencesRush University Medical CenterChicagoUSA

Personalised recommendations